Previous Close | 212.39 |
1-Year Change | 26.77% |
6-Months Change | 60.95% |
3-Months Change | 37.26% |
Moving Avg (50d) | 206.47 |
Moving Avg (200d) | 169.46 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 287.4B |
Beta (3-Years) | 1.21 |
Revenue Growth (ttm) | 76.38% |
Net Profit Margin (ttm) | -43.52% |
Return On Assets (ttm) | -17.37% |
EPS (ttm) | -0.72 |
PE Ratio (ttm) | -294.99 |
Dividend Yield | % |
Asset Description: | BeiGene, Ltd. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-16 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
216.638 | 223.009 | 227.257 | 233.629 | 244.248 | 254.868 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |